Technology Deal Could Improve Drug Candidate Potential

Strasbourg, (France) and Quebec-based biopharmaceutical company Domain Therapeutics, which specialises in developing drug candidates targeting transmembrane receptors, has signed a licensing agreement for its bioSens-All™ technology with global business Bristol-Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. The deal included an upfront payment for access to the technology, with additional payments on identification of development candidates.

“Through the work done using the technology on a wide variety of targets and in a wide range of indications, this agreement will fit well with its goal of delivering innovative medicines in key disease areas,” said Pascal Neuville, chief executive officer of Domain Therapeutics. “By generating a better understanding of what happens when a molecule binds to a target, we believe that bioSens-All™ is a key platform for improved candidate identification and reduced early stage attrition.”
The technology generates and analyses signalling data on G protein-couple receptors (GPCRs) drug candidates, potentially accelerating the discovery and development of biased drugs. It can monitor several dozen signalling pathways, in living cells, in parallel assays and in a homogeneous format. This allows the link to be made between specific signalling signatures of drug candidates and their biological effects.